LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-21. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
As it is now accepted that not only transition metals, but also anions in cathodes participate in redox activity necessary for lithium insertion and removal, the design of cathode materials with diverse transition metal cations increasingly consider also oxygen redox reactions in lithium-ion battery cathodes and how these may enhance capacity beyond transition metal limitations, with computational studies using density functional theory helping to optimize materials while minimizing structural degradation. Advances in anionic redox understanding have led to stabilization strategies like surface fluorination, improving cycling stability and safety.
The predecessor to Burger King was founded in 1953 in Jacksonville, Florida, as Insta-Burger King. After visiting the McDonald brothers' original store location in San Bernardino, California, the founders and owners (Keith G. Cramer and his wife's uncle Matthew Burns), who had purchased the rights to two pieces of equipment called "Insta-machines", opened their first restaurants. Their production model was based on one of the machines they had acquired, an oven called the "Insta-Broiler". This strategy proved so successful that they later required all their franchises to use the device. After the company faltered in 1959, it was purchased by its Miami, Florida, franchisees, James McLamore and David R. Edgerton. They initiated a corporate restructuring of the chain, first renaming the company Burger King. They ran the company as an independent entity for eight years (eventually expanding to over 250 locations in the United States), before selling it to the Pillsbury Company in 1967. Pillsbury's management tried several times to restructure Burger King during the late 1970s and the early 1980s. The most prominent change came in 1978 when Burger King hired McDonald's executive Donald N. Smith to help revamp the company. In a plan called "Operation Phoenix", Smith restructured corporate business practices at all levels of the company. Changes included updated franchise agreements, a broader menu and new standardized restaurant designs. Smith left Burger King for PepsiCo in 1980 shortly before a system-wide decline in sales.
==== Cancer health claims ==== The U.S. Food and Drug Administration initiated a process of reviewing and approving food and dietary supplement health claims in 1993. Reviews of petitions results in proposed claims being rejected or approved. If approved, specific wording is allowed on package labels. In 1999, a second process for claims review was created. If there is not a scientific consensus on the totality of the evidence, a Qualified Health Claim (QHC) may be established. The FDA does not "approve" qualified health claim petitions. Instead, it issues a Letter of Enforcement Discretion that includes very specific claim language and the restrictions on using that wording. The first QHCs relevant to vitamin E were issued in 2003: "Some scientific evidence suggests that consumption of antioxidant vitamins may reduce the risk of certain forms of cancer." In 2009, the claims became more specific, allowing that vitamin E might reduce the risk of renal, bladder and colorectal cancers, but with required mention that the evidence was deemed weak and the claimed benefits highly unlikely. A petition to add brain, cervical, gastric and lung cancers was rejected. A further revision, May 2012, allowed that vitamin E may reduce risk of renal, bladder and colorectal cancers, with a more concise qualifier sentence added: "FDA has concluded that there is very little scientific evidence for this claim." Any company product label making the cancer claims has to include a qualifier sentence.
Charles Jerrard. For services to the British Limbless Ex-Service Men's Association in Romford, Essex. Andy Derrick Johnson, Section Leader, Mathematics and Technology Department, Southwark College, London. For services to Education. George Refoy Johnston, Vice Chairman, Eildon Housing Association. For services to Housing. Samuel Hans Johnston, Process and General Supervisory Grade D, Ministry of Defence. Carol Theresa Jones, lately Senior Personal Secretary, the Highways Agency, Department of Transport. David Charles Newhams Jones, lately Journalist, Ashton Reporter. For services to Journalism in Lancashire. David Lloyd Jones, lately Chief Executive, Arfon Borough Council. For services to Local Government. Howard Leslie Jones, Maintenance Technician, Stanlow Manufacturing Complex, Shell UK Ltd. For services to Health and Safety. Ivy Jones. For services to the community in Tayside. Janice Jones. For services to the community, particularly Young Children, in Adamsdown, Cardiff. Robert Meinon Jones. For services to Choral Music in the District of Ffestiniog, Gwynedd. Lieutenant Colonel Robert Ian Hywel-Jones, , Senior Executive Officer, Foreign and Commonwealth Office. Trevor Mostyn Jones. For services to the Environment in North East England. Vera Daisy Jones. For political and public service. Wendy Keene. For political service. Eileen Grace Kelly. For services to the community in Pulborough, West Sussex. Donald Fraser Kennedy, Honorary Chairman, Dalneigh Senior Citizen's Club. For services to Elderly People in Inverness. Richard Leighton Keys.
=== Welfare of unorganized workers === The Labour Department under Lad has also pursued measures aimed at extending social-security coverage to workers outside conventional organized employment. In 2024, the state introduced the Ambedkar Karmikara Sahaya Hasta Yojane for additional categories of unorganized workers, with benefits including insurance and other forms of assistance. In 2025, Lad proposed a ₹1-per-litre fuel cess to create a dedicated healthcare fund for unorganized workers. He said such a mechanism could generate substantial resources for worker healthcare and support a proposed health-card system.
Sources: en.wikipedia.org
The college's prospectus, published in 1884, offered three diplomas: Christian Scientist (C.S.) for Christian Scientists' Association members; Christian Metaphysician (C.M.) for Eddy's 12-lesson course and three years' practice; and Doctor of Christian Science (D.C.S.) for C.M.s whose "life and character conform to Divine science." In 1886, the Bachelor of Christian Science (C.S.B.) diploma was offered. Students could study metaphysics, science of the scriptures, mental healing and obstetrics, using two textbooks, Science and Health and the Bible. Between 1881 and October 1889, when Eddy closed the college, 4,000 students took the course at $300 per person or married couple, making her a rich woman. Mark Twain wrote sarcastically that she had turned a sawdust mine (possibly Quimby's) into a Klondike.
Darlene was granted power of attorney over Bev's finances, until late in the second season of The Conners, when the 94-year-old Bev, angry that Darlene allowed Jackie and Becky to re-open the Lunch Box restaurant (an asset Bev somehow secretly retained), revoked Darlene having power of attorney.
Classification and Evolution Regulation, Development, and Molecular Diversity Aquatic Environments and Populations Ecology and Biodiversity Management History of Earth Men, Nature, and Societies, and Prehistory The diffusion departments are:
It is not significantly produced in nuclear reactors because 243Pu has a short half-life, but some is produced in nuclear explosions. 244Pu has been found in interstellar space and has the second longest half-life of any non-primordial radioisotope.
Dutasteride has been found to be significantly more effective than finasteride in the treatment of scalp hair loss in men, which has been attributed to its more complete inhibition of 5α-reductase and by extension decrease in DHT production. In addition to their antiandrogenic uses, 5α-reductase inhibitors have been found to reduce adverse affective symptoms in premenstrual dysphoric disorder in women. This is thought to be due to prevention by 5α-reductase inhibitors of the conversion of progesterone into allopregnanolone during the luteal phase of the menstrual cycle. 5α-Reductase inhibitors are sometimes used as a component of feminizing hormone therapy for transgender women in combination with estrogens and/or other antiandrogens. They may have beneficial effects limited to improvement of scalp hair loss, body hair growth, and possibly skin symptoms such as acne. However, little clinical research on 5α-reductase inhibitors in transgender women has been conducted, and evidence of their efficacy and safety in this group is limited. Moreover, 5α-reductase inhibitors have only mild and specific antiandrogenic activity, and are not recommended as general antiandrogens. 5α-Reductase inhibitors have minimal side effects and are well tolerated in both men and women. In men, the most common side effect is sexual dysfunction (0.9–15.8% incidence), which may include decreased libido, erectile dysfunction, and reduced ejaculate. Another side effect in men is breast changes, such as breast tenderness and gynecomastia (2.8% incidence).
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.